This clinical trial is focused on studying a condition called Generalized Myasthenia Gravis (gMG), which is a chronic autoimmune disease that causes muscle weakness. The study is testing a treatment called Batoclimab, also known by its code name IMVT-1401. Batoclimab is a solution for injection that is administered under the skin. The trial will compare the effects of Batoclimab to a placebo, which looks like the treatment but does not contain any active ingredients.

The purpose of the study is to evaluate how effective and safe Batoclimab is as a treatment for adults with Generalized Myasthenia Gravis. Participants in the study will receive either Batoclimab or a placebo. The study will monitor changes in the participants’ ability to perform daily activities, which is an important measure of how the disease affects their lives. The trial will last for several weeks, during which participants will receive regular injections and attend follow-up visits to assess their progress.

Throughout the study, researchers will carefully observe the participants to see how their symptoms change and to ensure their safety. The goal is to determine if Batoclimab can help improve the quality of life for people living with Generalized Myasthenia Gravis by reducing muscle weakness and improving their ability to carry out daily tasks. This study is an important step in finding new and effective treatments for this challenging condition.